This listing is provided strictly for in vitro laboratory research. It is not a drug, supplement, food, or medical product, is not for human or veterinary use, and has not been evaluated by the FDA. By purchasing you certify that you are at least 21 years of age and a qualified researcher acquiring this material solely for lawful laboratory research.
CL-2TZ
A 39-residue synthetic peptide engineered as a dual agonist of the glucose-dependent insulinotropic polypeptide receptor (GIPR) and the incretin receptor. Carries a C20 fatty diacid moiety for albumin binding. Studied in metabolic research for additive effects on insulin secretion and lipid metabolism versus single-receptor agonists.
Free COA included · Free shipment protection · 99%+ purity by HPLC & MS · Lyophilized powder
Certificate of Analysis — Included Free
Every batch independently tested by U.S.-accredited labs. Lot-matched COA confirms identity, purity ≥99% by HPLC, and safety screening.
Research Overview
CL-2TZ is a synthetic 39-amino acid peptide designed to act as a balanced dual agonist of the GIP receptor (GIPR) and the incretin receptor. The peptide scaffold is based on the native GIP sequence with strategic modifications to confer incretin receptor activity, plus a C20 fatty diacid moiety at lysine 26 for albumin binding and extended half-life.
In vitro receptor binding assays using GIPR- and incretin-receptor-expressing cell lines have characterized CL-2TZ's balanced agonism, demonstrating cAMP induction at both receptors with comparable potency. Comparative studies with selective incretin receptor agonists have explored whether dual receptor activation produces synergistic versus additive effects on glucose-stimulated insulin secretion.
Rodent and non-human primate research has examined CL-2TZ's effects on body weight, adipose tissue lipolysis, hepatic steatosis, and pancreatic beta-cell function. Mechanistic studies have focused on the distinct intracellular signaling cascades activated downstream of GIPR vs. the incretin receptor, including differences in beta-arrestin recruitment and receptor internalization.
All referenced studies are preclinical or in vitro. Not for human use.
Molecular Information
| Full Name / IUPAC | CL-2TZ |
| CAS Number | 2023788-19-2 |
| Molecular Formula | C₂₂₅H₃₄₈N₄₈O₆₈ |
| Molecular Weight | 4,813.5 g/mol |
| Sequence / Structure | 39-aa dual incretin agonist; C20 FA at K26 |
| Appearance | White lyophilized powder |
| Solubility | Soluble in sterile water or PBS |
| Format | Lyophilized (freeze-dried) powder |
| SKU | CL-2TZ |
Quality & Testing
- Purity: ≥99% by HPLC
- Identity: Confirmed by Mass Spectrometry (LC-MS)
- Heavy Metals: Screened; below detection thresholds
- Endotoxin: Tested per LAL assay
- Lot Tracking: Lot number on every vial matches published COA
- Packaging: Nitrogen-purged, sealed glass vials
Storage & Handling
- Short-term: Room temperature (15–25°C), dry, dark — up to 4 weeks
- Long-term: Refrigerated at 2–8°C — up to 18 months lyophilized
- Extended: −20°C; avoid freeze-thaw cycling
- Reconstitute in sterile water. Stable 30 days at 4°C post-reconstitution; lyophilized stock at −20°C.
This compound is supplied for in vitro research and laboratory use only. It is not for human or veterinary use, is not a drug or dietary supplement, and has not been evaluated or approved by the FDA or any regulatory agency for any therapeutic application. Purchasers must be 18 years of age or older and qualified researchers operating in compliance with all applicable local, state, and federal regulations governing research chemicals.
